Literature DB >> 28487302

Prophylactic use of eculizumab during surgery in chronic cold agglutinin disease.

Eirik Tjønnfjord1, Øystein A Vengen2, Sigbjørn Berentsen3, Geir Erland Tjønnfjord4.   

Abstract

Primary chronic cold agglutinin disease (CAD) is an autoimmune haemolytic anaemia in which a specific bone marrow lymphoproliferative disorder causes production of cold agglutinins (CA). Binding of CA to erythrocyte surface antigens results in a predominantly extravascular haemolysis that is entirely complement dependent. Because of complement activation, exacerbations are common during febrile infections, trauma or major surgery. Involvement of the terminal complement pathway with C5-mediated intravascular haemolysis is probably not prominent in stable disease but is supposed to be of importance in exacerbations following acute phase reaction.We report on a patient with CAD prone to exacerbation of haemolysis during acute phase reactions who was scheduled for cardiac surgery. To prevent her having an exacerbation of haemolysis, we chose to treat her prophylactically with eculizumab along with the usual perioperative precautions. Aortic valve replacement was undertaken with full cardiopulmonary bypass at normothermia. The procedure was successful; no exacerbation of haemolysis was observed, and transfusion requirements did not exceed what could be expected. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Drug therapy related to surgery; Haematology (drugs and medicines); Haematology (incl blood transfusion)

Mesh:

Substances:

Year:  2017        PMID: 28487302      PMCID: PMC5612509          DOI: 10.1136/bcr-2016-219066

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Acute phase haemolysis in chronic cold agglutinin disease.

Authors:  E Ulvestad; S Berentsen; T E Mollnes
Journal:  Scand J Immunol       Date:  2001 Jul-Aug       Impact factor: 3.487

Review 2.  Cold agglutinin disease.

Authors:  Paul L Swiecicki; Livia T Hegerova; Morie A Gertz
Journal:  Blood       Date:  2013-06-11       Impact factor: 22.113

Review 3.  Cold agglutinin-mediated autoimmune hemolytic anemia.

Authors:  Sigbjørn Berentsen; Ulla Randen; Geir E Tjønnfjord
Journal:  Hematol Oncol Clin North Am       Date:  2015-03-12       Impact factor: 3.722

4.  Immunoglobulin heavy and light chain gene features are correlated with primary cold agglutinin disease onset and activity.

Authors:  Agnieszka Małecka; Gunhild Trøen; Anne Tierens; Ingunn Østlie; Jędrzej Małecki; Ulla Randen; Sigbjørn Berentsen; Geir E Tjønnfjord; Jan M A Delabie
Journal:  Haematologica       Date:  2016-05-19       Impact factor: 9.941

Review 5.  The cold hemagglutinin disease.

Authors:  H Schubothe
Journal:  Semin Hematol       Date:  1966-01       Impact factor: 3.851

6.  Paradoxical haemolysis in a patient with cold agglutinin disease.

Authors:  E Ulvestad
Journal:  Eur J Haematol       Date:  1998-02       Impact factor: 2.997

7.  Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.

Authors:  Sigbjørn Berentsen; Elling Ulvestad; Ruth Langholm; Klaus Beiske; Henrik Hjorth-Hansen; Waleed Ghanima; Jon Hjalmar Sørbø; Geir E Tjønnfjord
Journal:  Haematologica       Date:  2006-04       Impact factor: 9.941

8.  Cold agglutinins in patients undergoing cardiac surgery requiring cardiopulmonary bypass.

Authors:  David W Barbara; William J Mauermann; James R Neal; Martin D Abel; Hartzell V Schaff; Jeffrey L Winters
Journal:  J Thorac Cardiovasc Surg       Date:  2013-04-13       Impact factor: 5.209

9.  Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma.

Authors:  Ulla Randen; Gunhild Trøen; Anne Tierens; Chloé Steen; Abdirashid Warsame; Klaus Beiske; Geir E Tjønnfjord; Sigbjørn Berentsen; Jan Delabie
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941

10.  TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins.

Authors:  Ju Shi; Eileen L Rose; Andrew Singh; Sami Hussain; Nancy E Stagliano; Graham C Parry; Sandip Panicker
Journal:  Blood       Date:  2014-04-02       Impact factor: 22.113

  10 in total
  3 in total

1.  Lessons of the month 1: Polytrauma in a geriatric patient resulting in reactivation of cytomegalovirus infection and secondary cold agglutinin disease-induced haemolytic anaemia.

Authors:  Thomas Stockdale; Tom Hosack; Cameron Griffiths; Amit Kj Mandal; Constantinos G Missouris
Journal:  Clin Med (Lond)       Date:  2020-06-17       Impact factor: 2.659

Review 2.  Autoimmune hemolytic anemia.

Authors:  Anita Hill; Quentin A Hill
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia.

Authors:  Sigbjørn Berentsen
Journal:  Front Immunol       Date:  2020-04-07       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.